The bipartisan Federal Aviation Administration reauthorization is a big win for travelers, the aviation workforce, and our economy. It will expand critical protections for air travelers, strengthen safety standards, and support pilots, flight attendants, and air traffic controllers.
It also builds on my Administration’s efforts to improve the travel experience for airline passengers, affirming the Department of Transportation’s rule that mandated automatic refunds when flights are cancelled or significantly delayed. It also makes sure families can sit together without paying extra fees. Passengers shouldn’t have to jump through endless hoops just to get the refunds that they are owed, and corporations shouldn’t rip off hardworking Americans through hidden junk fees.
I want to thank members of both parties who worked together over many months to pass this long-term reauthorization.
The bipartisan Federal Aviation Administration reauthorization is a big win for travelers, the aviation workforce, and our economy. It will expand critical protections for air travelers, strengthen safety standards, and support pilots, flight attendants, and air traffic controllers. It also builds on my Administration’s efforts to improve the travel experience for airline passengers, affirming the Department… Continue reading Statement from President Joe Biden After Signing FAA Reauthorization Act
Read MorePublished on: 25 Apr 2024, under Press Releases Cambridge, UK, April 25, 2024: Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has secured funding from the Bill & Melinda Gates Foundation (“the Gates Foundation” or “the foundation”). The funding is comprised of a… Continue reading Owlstone Medical Secures $6.5 Million to Support Development of Breath-based Diagnostics for Infectious Disease
Read MorePublished on: 9 Nov 2023, under Science & Research Cambridge, UK, November 9, 2023: Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the results of a peer-reviewed study in the journal Biomedicines – ‘Exogenous Volatile Organic Compound (EVOC®) Breath Testing Maximizes Classification Performance for Subjects with Cirrhosis… Continue reading Owlstone Medical Publishes Exciting Liver Data on the use of an EVOC® Probe for the Early Detection of Cirrhosis
Read More
Cabin Air Sensor Solutions Ltd, (CASS) announced today that they had successfully completed their 9-month compound sensing work package adding Ethanol, Ammonia, Acetone, Toluene, Tricresyl Phosphate & Carbon Monoxide to their compound detection capability.
Read More